- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 265/28 - 1,4-OxazinesHydrogenated 1,4-oxazines
Patent holdings for IPC class C07D 265/28
Total number of patents in this class: 66
10-year publication summary
|
2
|
4
|
7
|
2
|
3
|
10
|
2
|
4
|
2
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 670 |
4 |
| Bristol-myers Squibb Company | 4863 |
2 |
| Amgen Inc. | 3899 |
2 |
| Ricoh Company, Ltd. | 13216 |
2 |
| Adverio Pharma GmbH | 44 |
2 |
| BioCryst Pharmaceuticals, Inc. | 176 |
2 |
| Oregon Health & Science University | 758 |
2 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 806 |
2 |
| Kemimedi Co.Ltd | 3 |
2 |
| Cullgen (Shanghai), Inc. | 32 |
2 |
| Vigil Neuroscience, Inc. | 42 |
2 |
| Merck Sharp & Dohme LLC | 3751 |
2 |
| Glaxosmithkline LLC | 539 |
1 |
| Hoffmann-La Roche Inc. | 3267 |
1 |
| Baker Hughes Incorporated | 5504 |
1 |
| 3m Innovative Properties Company | 17957 |
1 |
| BASF SE | 20432 |
1 |
| The Regents of the University of California | 19517 |
1 |
| International Business Machines Corporation | 60129 |
1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 93 |
1 |
| Other owners | 32 |